Aldeyra Therapeutics stock plunges on heavy volume after FDA finds 'substantive' issues with NDA for dry-eye disease treatment
Shares of Aldeyra Therapeutics Inc. (ALDX) plummeted 61.9% toward a 3 1/2-year low in very active morning trading Monday, enough to pace the Nasdaq's decliners, after the Massachusetts-based biotechnology company said the U.S. Food and Drug Administration identified "substantive review issues" with the new dug application (NDA) for its dry-eye disease treatment reproxalap. Trading volume ballooned to 12.3 million shares, compared with the full-day average of about 566,000 shares. In minutes from a late-cycle review meeting, the FDA stated, "[i]t does not appear that you have data to support the clinical relevance of the ocular signs to support your dry eye indication." The company said it submitted responses to the FDA regarding the review issues, but the FDA said additional clinical trials were needed to satisfy efficacy requirements. Given that the NDA review cycle ends on Nov. 23, Aldeyra said the FDA may not be in position to approve the NDA. Aldeyra's stock, which was headed for the lowest close since April 3, 2020, has plunged 73.6% over the past three months, while the iShares Biotechnology ETF (IBB) has lost 5.2% and the S&P 500 has eased 2.9%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-16-23 1150ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track